Relay Therapeutics vs Profluent Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge MA precision oncology biotech using Dynamo platform to exploit protein motion for drug design; lead asset RLY-2608 targets PI3Kα in breast cancer.
About
Relay Therapeutics was founded in 2016 in Cambridge, Massachusetts, emerging from research at MIT and D.E. Shaw Research. The company is built around its Dynamo platform, which integrates computational protein motion modeling (molecular dynamics simulations) with structural biology and medicinal chemistry to design small-molecule drugs that exploit the dynamic conformational states of disease-relevant proteins—a dimension traditional structure-based drug design ignores.\n\nRelay's lead program, RLY-2608, is a first-in-class allosteric, mutant-selective PI3Kα inhibitor for advanced breast cancer patients with PI3KCA mutations. Unlike approved PI3Kα inhibitors that cause metabolic toxicity by inhibiting wild-type PI3Kα in normal tissues, RLY-2608 selectively targets the mutant form. The compound has shown early clinical promise including objective responses in patients who progressed on prior alpelisib, supporting a differentiated profile. Additional programs target FGFR2 and SHP2 in solid tumors.\n\nRelay has raised over $1.2 billion in equity financing and holds substantial cash reserves. The company is conducting multiple clinical trials and building a pipeline that validates its Dynamo-guided discovery approach. Though revenue-stage remains early, Relay represents a leading example of next-generation computational oncology companies seeking to turn protein dynamics insights into selective, differentiated medicines.
AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.
About
Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.